Nrf2 activation for kidney disease treatment-a mixed blessing?

Masahiro Nezu; Norio Suzuki

doi:10.1016/j.kint.2020.08.033

Nrf2 activation for kidney disease treatment-a mixed blessing?

Kidney Int. 2021 Jan;99(1):20-22. doi: 10.1016/j.kint.2020.08.033.

Authors

Masahiro Nezu¹, Norio Suzuki²

Affiliations

¹ Division of Oxygen Biology, United Centers for Advanced Research and Translational Medicine, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan; Department of Endocrinology and Diabetes, Yamanashi Prefectural Central Hospital, Kofu, Yamanashi, Japan.
² Division of Oxygen Biology, United Centers for Advanced Research and Translational Medicine, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan. Electronic address: sunorio@med.tohoku.ac.jp.

PMID: 33390228
DOI: 10.1016/j.kint.2020.08.033

Abstract

Activation of cellular antioxidative signaling is expected to be a silver bullet against kidney diseases, and clinical trials of compounds activating the antioxidant transcription factor Nrf2 have revealed their renoprotective effects. However, cardiac events have been observed in some cases with elevated urinary albumin excretion in these trials. Therefore, elucidating the negative effects of Nrf2 activation is essential. Rush and colleagues demonstrated that Nrf2 activation aggravates podocyte injury, a factor related to proteinuria and cardiac failure.

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Animals
Antioxidants / therapeutic use
Mice
NF-E2-Related Factor 2 / genetics
Podocytes*
Proteinuria
Renal Insufficiency, Chronic*

Substances

Antioxidants
NF-E2-Related Factor 2